Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment
Conditions
- Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Recurrent Nodal Marginal Zone Lymphoma
- Recurrent Splenic Marginal Zone Lymphoma
- Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Splenic Marginal Zone Lymphoma
Interventions
- PROCEDURE: Biospecimen Collection
- PROCEDURE: Bone Marrow Biopsy
- PROCEDURE: Computed Tomography
- BIOLOGICAL: Mosunetuzumab
- DRUG: Polatuzumab Vedotin
- PROCEDURE: Positron Emission Tomography
- OTHER: Survey Administration
- DRUG: Zanubrutinib
Sponsor
SWOG Cancer Research Network
Collaborators